Cell Signaling Technology

Product Pathways - Apoptosis

TRAF6 (D21G3) Rabbit mAb #8028

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP H Mk Endogenous 60 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

TRAF6 (D21G3) Rabbit mAb recognizes endogenous levels of total TRAF6 protein. This antibody is not predicted to cross-react with other TRAF family members.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human TRAF6 protein.

Western Blotting

Western Blotting

Western blot analysis of extracts from 293T cells, either mock transfected (-) or transfected with a cDNA expression construct encoding full-length human TRAF6 (+), using TRAF6 (D21G3) Rabbit mAb.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using TRAF6 (D21G3) Rabbit mAb.

Background

TRAFs (TNF receptor-associated factors) are a family of multifunctional adaptor proteins that bind to surface receptors and recruit additional proteins to form multiprotein signaling complexes capable of promoting cellular responses (1-3). Members of the TRAF family share a common carboxy-terminal "TRAF domain" which mediates interactions with associated proteins; many also contain amino-terminal Zinc/RING finger motifs. The first TRAFs identified, TRAF1 and TRAF2, were found by virtue of their interactions with the cytoplasmic domain of TNF-receptor 2 (TNFRII) (4). The six known TRAFs (TRAF1-6) act as adaptor proteins for a wide range of cell surface receptors and participate in the regulation of cell survival, proliferation, differentiation, and stress responses.

TRAF6 plays a critical role in innate and adaptive immunity, bone metabolism, and development of certain tissues including the nervous system (5).TRAF6 deficiency results in osteopetrosis and defective IL-1, CD40, and LPS signaling (6) as well as defects in neuronal development (7). Unlike other TRAF family members that mediate signaling through TNF, TRAF6 has unique binding activities (8) that result in signaling responses from the interleukin-1 receptor (IL-1R) (9), toll-like receptor (10,11), CD40 (12), RANK (13,14), and p75 neurotrophin receptor (15). TRAF6 associates directly with CD40 and RANK, and indirectly with IL-1R/TLR through IRAK (10). This leads to activation of NF-κB and MAP kinase signaling pathways through downstream association with the TAB/TAK-1 complex (16). TRAF6 also activates Src family nonreceptor tyrosine kinases leading to Akt activation (17).

  1. Arch, R.H. et al. (1998) Genes Dev. 12, 2821-2830.
  2. Chung, J. Y. et al. (2002) J. Cell Sci. 115, 679-688.
  3. Bradley, J.R. and Pober, J.S. (2001) Oncogene 20, 6482-6491.
  4. Rothe, M. et al. (1994) Cell 78, 681-692.
  5. Wu, H. and Arron, J.R. (2003) Bioessays 25, 1096-105.
  6. Lomaga, M.A. et al. (1999) Genes Dev 13, 1015-24.
  7. Lomaga, M.A. et al. (2000) J Neurosci 20, 7384-93.
  8. Ye, H. et al. (2002) Nature 418, 443-7.
  9. Cao, Z. et al. (1996) Nature 383, 443-6.
  10. Muzio, M. et al. (1997) Science 278, 1612-5.
  11. Medzhitov, R. et al. (1998) Mol Cell 2, 253-8.
  12. Ishida, T. et al. (1996) J Biol Chem 271, 28745-8.
  13. Darnay, B.G. et al. (1998) J Biol Chem 273, 20551-5.
  14. Wong, B.R. et al. (1998) J Biol Chem 273, 28355-9.
  15. Khursigara, G. et al. (1999) J Biol Chem 274, 2597-600.
  16. Ninomiya-Tsuji, J. et al. (1999) Nature 398, 252-6.
  17. Wong, B.R. et al. (1999) Mol Cell 4, 1041-9.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products